- Login / Register
- 0 items - ₺0.00
- English
AGENDA
Ali Raif Pharmaceuticals Tops Trademark Filings from Its R&D Center Results have been announced for Türkiye’s Top 250 Companies with the highest R&D spending. Turkishtime’s 2023 R&D 250 Research has ranked Ali Raif İlaç ranked first in the number of trademarks secured at its R&D Center. Turkishtime’s 11th annual cross-sector report on Turkish industry draws […]
The Ali Raif Human Resources Directorate team won the third-place award in the 2022 TEGEP Education and Development Awards, organized by the Association of Education and Development Platform of Turkey. Since 2015, the TEGEP Education and Development Awards celebrates the best corporate education and development practices in Turkey to promote and recognize good practices. And […]
The economy and business portal Turkishtime published its ninth annual R&D 250 research. Based on 2021 data, Ali Raif became one of the “Highest R&D Spenders in Turkey” and placed fifth in all industries and fourth in the pharmaceutical industry in terms of the number of trademarks obtained in the R&D center. Ali Raif draws […]
August 2021 Fortune magazine continues to rank the largest companies in Turkey, just as it does in the United States, based on annual net turnover, exports, and profitability before tax, etc. Ali Raif İlaç continues its steady climb on the Fortune 500 List, which saw its 14th instalment this year. The Fortune 500 list includes […]
The Company Aims to Quadruple its Production Capacity Established in 1928, Ali Raif İlaç Sanayi has a deep-rooted history and an important place in the Turkish pharmaceutical industry with its 58 years of experience in the field. The company has now taken an important step in line with its growth targets and broke ground for […]
Ali Raif İlaç R&D Director Serdar Ünlü, Ph.D., answering the questions from Fortune magazine’s special issue on R&D, emphasized that the only way to shape the future of the Turkish pharmaceutical industry and have a presence in global markets is to engage in innovative R&D efforts and undertake the correct management of industrial rights that […]
As a company whose mission for 58 years has been to provide high-quality services and products that protect and improve human health, Ali Raif İlaç was awarded the grand prize in the Pharmaceutical Company With the Most Brands in the R&D Center category at the 9th International Pharmaceutical Chemistry Congress R&D Awards. After engaging in […]
Ali Raif İlaç Sanayi became the “curiosity sponsor” of 120 children in the Science Campaign organized by the Young Guru Academy (YGA), a non-governmental organization, to spread the motto “Adding Value to Life” as part of the Mother’s Day celebrations. The company sponsored the curiosity of 60 fifth- and sixth-grade students at Şehit Serkan Angay […]
The 18th Human Resources Summit sponsored by Kariyer.net has united the human resources community in the Respect for Human Awards, which are presented to companies that respond to 100 percent of candidate applications, create the most jobs and receive the highest number of applications. On the evening of May 2, more than 20,000 employers were […]
-
Down syndrome is not a disease, but a genetic condition.
We frequently hear that DNA is genetic blueprint of life. Just as a thread wound neatly around a spool, a cell wraps the DNA in the nucleus with a similar mechanism. All traits of a living being are stored in the DNA of its genes. Chromosomes are genetic units created by condensation of DNA, which pass on hereditary characteristics for all life forms. Humans have 23 pairs of chromosomes. Read More
-
Common Cold and Flu
The common cold and the flu are frequently confused even though they are two different conditions.
The most important difference between a common cold and the flu is that the former is not accompanied by fever and overall discomfort while the latter is. Flu is also characterized by secondary bacterial infections. Common cold starts with nasal congestion, nasal flow (runny nose), sore throat and cough. A cold is usually treated symptomatically and clears up within a few days. Read More
-
Cardiac Risk
Mortality statistics of the Turkish Statistical Institute reveal that 408,782 people died in Turkey in 2016. Consistent with global statistics, the most common cause of death in Turkey is cardiovascular diseases (approximately 40 percent, 162,876 people). Read More
-
Attention Deficit Hyperactivity Disorder
The attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by a short/distractible attention span, mobility and impulsiveness*, and that is usually lifelong (APA 2013). Read More
Videos
Ali Raif Pharmaceuticals Tops Trademark Filings from Its R&D Center Results have been announced for Türkiye’s Top 250 Companies with the highest R&D spending. Turkishtime’s 2023 R&D 250 Research has ranked Ali Raif İlaç ranked first in the number of trademarks secured at its R&D Center. Turkishtime’s 11th annual cross-sector report on Turkish industry draws […]
Ali Raif İlaç joined the pharmaceutical industry in 1963 to “add value to life,” and celebrates its lifetime success on its 60th anniversary. Ali Raif İlaç has always upheld its values and pursued innovative and future-oriented interests in products and services for the benefit of public health. The firm has pioneered many perspectives and achievements […]
The Ali Raif Human Resources Directorate team won the third-place award in the 2022 TEGEP Education and Development Awards, organized by the Association of Education and Development Platform of Turkey. Since 2015, the TEGEP Education and Development Awards celebrates the best corporate education and development practices in Turkey to promote and recognize good practices. And […]
The economy and business portal Turkishtime published its ninth annual R&D 250 research. Based on 2021 data, Ali Raif became one of the “Highest R&D Spenders in Turkey” and placed fifth in all industries and fourth in the pharmaceutical industry in terms of the number of trademarks obtained in the R&D center. Ali Raif draws […]
Ali Raif İlaç Sanayi A.Ş. Kurumsal Kimlik bilgileri için tıklayınız.
Our General Manager Nihal Arslan answered questions from WORKSHOP magazine. September 2021 Can you tell us briefly about your professional background? I graduated from Istanbul Technical University Faculty of Chemical Metallurgy Department of Chemical Engineering in 1984. I then completed the MBA program at Istanbul University Institute of Business Economics. I started my career in […]
August 2021 Fortune magazine continues to rank the largest companies in Turkey, just as it does in the United States, based on annual net turnover, exports, and profitability before tax, etc. Ali Raif İlaç continues its steady climb on the Fortune 500 List, which saw its 14th instalment this year. The Fortune 500 list includes […]
The Company Aims to Quadruple its Production Capacity Established in 1928, Ali Raif İlaç Sanayi has a deep-rooted history and an important place in the Turkish pharmaceutical industry with its 58 years of experience in the field. The company has now taken an important step in line with its growth targets and broke ground for […]
Ali Raif İlaç R&D Director Serdar Ünlü, Ph.D., answering the questions from Fortune magazine’s special issue on R&D, emphasized that the only way to shape the future of the Turkish pharmaceutical industry and have a presence in global markets is to engage in innovative R&D efforts and undertake the correct management of industrial rights that […]